Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ciprofloxacin, Rifampicin, Tigecycline, and Vancomycin Combination
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is an antibiotic combination regimen consisting of ciprofloxacin (a fluoroquinolone), rifampicin (an RNA polymerase inhibitor), tigecycline (a glycylcycline), and vancomycin (a glycopeptide). It has been studied for treating various challenging bacterial infections, particularly those involving difficult-to-treat pathogens or biofilm-associated infections. The combination is designed to leverage diverse mechanisms of action to enhance antimicrobial activity against pathogens like Staphylococcus aureus, coagulase-negative staphylococci, and Carbapenem-resistant Acinetobacter baumannii.
02
Targets
DNA gyrase30S A-site (Bacterial ribosomal 30S A-site)rpoB (DNA-directed RNA polymerase subunit beta)Topo IV (Bacterial Topoisomerase IV)D-Ala-D-Ala (D-Ala-D-Ala terminus)
Beyond the preview
Go deeper on Ciprofloxacin, Rifampicin, Tigecycline, and Vancomycin Combination.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ciprofloxacin, Rifampicin, Tigecycline, and Vancomycin Combination.